Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances DOI Creative Commons
Aline Maria de Oliveira Rocha, Gabriel Fidelis Ribeiro,

Juliana Capecce da Silva

et al.

Reumatologia/Rheumatology, Journal Year: 2024, Volume and Issue: 62(6), P. 447 - 455

Published: Dec. 24, 2024

To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life. A systematic review was carried out comparing known treatments immunobiological therapies, evaluating clinical improvement, adverse events prognosis. The MEDLINE, PubMed, LILACS Cochrane Library databases were used with children aged 0 to 18 diagnosed JDM. PRISMA 2020 statement followed throughout process. immunobiologics studied rituximab (RTX) anti-tumor necrosis factor drugs Disease Activity Score skin, Childhood Myositis Assessment Scale Manual Muscle Testing tools. There no difference response when RTX (early or late). anti-TNF studies a population that refractory initial showed significant muscle skin disease activity. For severe disease, biologics tend be medication best therapeutic response.

Language: Английский

Clinical implications of human Parvovirus B19 infection on autoimmunity and autoimmune diseases DOI

Chih-Chen Tzang,

Liang-Yun Chi,

Chenyu Lee

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 147, P. 113960 - 113960

Published: Jan. 1, 2025

Language: Английский

Citations

1
Adolescent-Onset Triple-Antibody Positive Juvenile Dermatomyositis Found in Hispanic Male Wrestler: A Case Report and Literature Review DOI Open Access

Rajvee Sanghavi,

Patrycja Tesmer,

Deepika Singh

et al.

Open Journal of Rheumatology and Autoimmune Diseases, Journal Year: 2025, Volume and Issue: 15(01), P. 36 - 42

Published: Jan. 1, 2025

Language: Английский

Citations

0
Juvenile Dermatomyositis Triggered by Influenza B: A Case Report on Viral‐Induced Autoimmunity DOI Creative Commons
S. Dans-Caballero,

M. Juan-Cencerrado,

Carmen Mochón‐Jiménez

et al.

Pediatric Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: May 6, 2025

ABSTRACT A previously healthy 13‐year‐old boy developed juvenile dermatomyositis (JDM) shortly after a confirmed influenza B infection, presenting with progressive proximal muscle weakness and classic cutaneous findings. Laboratory tests revealed elevated enzymes myositis‐specific autoantibodies, supporting the diagnosis. The temporal association suggests potential post‐viral autoimmune trigger, highlighting as possible environmental factor in JDM pathogenesis. This case reinforces need for heightened clinical awareness further research into virus‐associated mechanisms pediatric myopathies.

Language: Английский

Citations

0
Viral Myositis and Dermatomyositis: Key Diagnostic Differences DOI Open Access
Ahmed Omar, Kapsok Li,

Ana I. Quintero-Del Rio

et al.

Open Journal of Rheumatology and Autoimmune Diseases, Journal Year: 2025, Volume and Issue: 15(02), P. 67 - 80

Published: Jan. 1, 2025

Language: Английский

Citations

0
Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases—A Narrative Review DOI Creative Commons
Ichiro Kobayashi

Children, Journal Year: 2024, Volume and Issue: 11(9), P. 1046 - 1046

Published: Aug. 27, 2024

Juvenile idiopathic inflammatory myopathy (JIIM) is a rare systemic autoimmune disease characterized by skeletal muscle weakness with or without skin rash. dermatomyositis (JDM) the most common subtype of JIIM, accounting for 80% JIIM. Recent studies identified several myositis-specific autoantibodies (MSAs) and myositis-associated (MAAs). Each MSA MAA associated distinct clinical features outcomes, although there are differences in prevalence MSA/MAA autoantibody–phenotype relationships between age ethnic groups. Histopathological have revealed critical roles type I interferons vasculopathy development JDM. Serological classification mostly corresponds to clinicopathological classification. Novel therapeutic agents, such as biologics Janus kinase inhibitors (JAKi), been developed; however, date, lack high-level evidence. As advances treatment reduced mortality rate recent focused on medium- long-term outcomes. However, rapidly progressive interstitial lung (RP-ILD) remains major cause death anti-melanoma differentiation gene 5 autoantibody-positive Early diagnosis intervention using multi-drug regimen RP-ILD. Rituximab JAKi may reduce patients JDM-associated RP-ILD refractory conventional therapy.

Language: Английский

Citations

2
The Role of Mycoplasma pneumoniae in the pathogenesis of autoimmune diseases: Mechanisms, complications, and therapeutic perspectives DOI Creative Commons

Anna Gwóźdź-Broczkowska,

Piotr Godlewski, Aisha Y. Hassan

et al.

Medical Science, Journal Year: 2024, Volume and Issue: 28(154), P. 1 - 10

Published: Dec. 30, 2024

Mycoplasma pneumoniae is a respiratory pathogen capable of causing severe extrapulmonary complications, including the development autoimmune diseases such as Guillain-Barré syndrome, systemic lupus erythematosus, and juvenile dermatomyositis.The pathogenic mechanisms involve molecular mimicry, activation Toll-like receptors (TLRs) TLR2 TLR4, disruptions in cytokine regulation, overproduction interleukin-17 (IL-17).Oxidative stress, inflammasome activation, metabolic alterations neutrophils further exacerbate inflammatory responses.Although infection usually not very severe, there growing evidence that pneumonia may be linked to onset disorders.This emphasizesthe necessity for more studies on this infection.High levels macrolide resistance, especially Asia, difficulties with diagnosis emphasize need new approaches prevention treatment.Studies have reported promising results Qingfei Tongluo Formula (QTF).This traditional Chinese medicine reduces inflammation mitigates risk autoimmunization by modulating oxidative stress PERK pathway.Future should consider Epstein-Barr virus (EBV) co-infection, which synergistically increase disease.The vaccines against M. an important long-term avenue.

Language: Английский

Citations

0
MIP-C: A new autoimmune rheumatic disease concomitant with the COVID-19 pandemic DOI Open Access

Katja Brion,

Maile Phillips,

Antonio La Cava

et al.

Rheumatology and Immunology Research, Journal Year: 2024, Volume and Issue: 5(3), P. 133 - 135

Published: Sept. 1, 2024

Language: Английский

Citations

0
Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances DOI Creative Commons
Aline Maria de Oliveira Rocha, Gabriel Fidelis Ribeiro,

Juliana Capecce da Silva

et al.

Reumatologia/Rheumatology, Journal Year: 2024, Volume and Issue: 62(6), P. 447 - 455

Published: Dec. 24, 2024

To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life. A systematic review was carried out comparing known treatments immunobiological therapies, evaluating clinical improvement, adverse events prognosis. The MEDLINE, PubMed, LILACS Cochrane Library databases were used with children aged 0 to 18 diagnosed JDM. PRISMA 2020 statement followed throughout process. immunobiologics studied rituximab (RTX) anti-tumor necrosis factor drugs Disease Activity Score skin, Childhood Myositis Assessment Scale Manual Muscle Testing tools. There no difference response when RTX (early or late). anti-TNF studies a population that refractory initial showed significant muscle skin disease activity. For severe disease, biologics tend be medication best therapeutic response.

Language: Английский

Citations

0